Xillix' (Canada) half-year revenues up 128%:
This article was originally published in Clinica
Executive Summary
In the six months ended February 28th, 1995, Xillix (Canada) reported revenues of Can$2.59 million, an increase of 128% compared with the first half of fiscal 1994. Product sales accounted for Can$1.46 million (up 59%): during the first half Xillix sold four LIFE Imaging Systems, 30 MicroImager digital cameras and two Automated Image Cytometer systems. Loss for the period was reduced slightly to Can$2.03 million from Can$2.53 million the year before. The Richmond, British Columbia-based company has recently completed a Can$7 million private placement.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.